Summary
We studied the association of estrogen receptor (ER) with several histologic variables that correlate with breast tumor differentiation and with patient prognosis. Contingency table analysis revealed highly statistically significant correlations between ER content and histologic and nuclear grades, tumor necrosis, and the degree of elastosis and lymphoid cell infiltration. ER positive tumors were more likely than ER negative tumors to demonstrate histological evidence of tumor differentiation. All tumors with histologic grade 1 or nuclear grade 1 (best differentiated) were ER positive or borderline positive. Eighty-nine percent of ER negative tumors were histologic grade 3 and 78.4% were nuclear grade 3 (poor differentiation). ER positive tumors were also correlated with absent tumor necrosis, higher elastic content, and absent lymphoid cell infiltration, all features of good differentiation. Medullary carcinomas were frequently (73%) ER negative, but no relationship between ER and other morphologic types of breast cancer or 9 other morphologic variables was found. ER appears to be a biochemical marker for the degree of differentiation of human breast cancer providing a rationale for the observed differences in biological behavior between receptor positive and negative tumors.
This is a preview of subscription content, log in via an institution to check access.
References
McGuire WL, Carbone PP, Vollmer EP: Estrogen receptors in human breast cancer. Raven Press, New York, 1975.
Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor is an independent prognostic factor for early recurrence in breast cancer. Can Res 37: 4669–4671, 1977.
Osborne CK, Knight WA, Yochmowitz MG, McGuire WL: Modern approaches to the treatment of breast cancer. Blood, in press, 1980.
Rich MA, Furmanski P, Brooks SC: Prognostic value of estrogen receptor determinations in patients with breast cancer. Can Res 38: 4296–4298, 1978.
Allegra JC, Lippman ME, Simon R, Thompson EB, Barlack A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The association between stroid hormone receptor status and disease free interval in breast cancer. Can Treat Rep 38: 4292–4295, 1979.
Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Can Res 38: 4292–4295, 1978.
Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979.
Cooke T, Shields R, George P, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet 2: 995–997, 1979.
Bishop HM, Blamey RW, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 2: 283–284, 1979.
Walt AJ, Singhakowinta A, Brooks SC, Cortez A: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80: 506–512, 1976.
Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45: 349–353, 1980.
McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Can Res 37: 637–639, 1977.
Fisher ER, Gregorio RM, Fisher B: The pathology of invasive breast cancer. A syllabus derived from the findings of the National Surgical Adjuvant Breast Project (Protocol No. 4). Cancer 36: 1–85, 1975.
Fisher ER, Gregorio RM, Redmond C, Dekker A, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). II. The significance of regional node histology other than sinus histiocytosis in invasive mammary cancer. Am J Clin Pathol 65: 21–30, 1976.
Fisher ER, Gregorio RM, Redmond C, Kim WS, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol 65: 439–444, 1976.
Fisher ER, Palekar AS, Gregorio RM, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). IV. Significance of tumor necrosis. Human Pathol 9: 523–530, 1978.
Nie N, Bent D, Hull C: Statistical package for the social sciences. McGraw-Hill, New York, 1970.
Meyer JS, Bauer WC, Rao BR: Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. Lab Invest 39: 225–235, 1978.
Meyer JS, Rao BR, Stevens SC, White WL: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40: 2290–2298, 1977.
Silvestrini R, Daidone MG, DiFronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665–670, 1970.
Fisher ER, Redmond C, and Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4) VI. Discriminants for 5 year treatment failure. Cancer, in press, 1980.
Author information
Authors and Affiliations
Additional information
Address for reprints: E.R. Fisher, M.D., Dept. of Pathology, Shadyside Hospital, 5230 Centre Ave., Pittsburgh, PA 15232.
Rights and permissions
About this article
Cite this article
Fisher, E.R., Osborne, C.K., McGuire, W.L. et al. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Tr 1, 37–41 (1981). https://doi.org/10.1007/BF01807890
Issue Date:
DOI: https://doi.org/10.1007/BF01807890